Publications by authors named "Hassnae Badi"
Safety, tolerability and immunogenicity of an active anti-Aβ vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trial.
Ana-María Lacosta María Pascual-Lucas Pedro Pesini Diego Casabona Virginia Pérez-Grijalba Hassnae Badi
Alzheimers Res Ther
January 2018
Article Synopsis
- A new active vaccine, ABvac40, targeting the amyloid-β peptide was developed for Alzheimer's disease and tested in a phase I clinical trial for safety and tolerability.
- The trial involved 24 patients with mild to moderate AD, who were randomly assigned to receive either the vaccine or a placebo, with a focus on documenting any adverse effects and measuring immune response.
- Initial results showed that both groups experienced similar rates of adverse events, suggesting that the vaccine was generally safe and tolerated, but no significant differences were found in the occurrence of specific imaging abnormalities related to amyloid treatment.
The two pathognomonic lesions in the brain of AD patients are senile plaques and intraneuronal neurofibrillary tangles (NFT). Previous studies have demonstrated that amyloid-β (Aβ) is a component of both senile plaques and NFTs, and have showed that intracellular accumulation of Aβ is toxic for cells and precedes the appearance of extracellular amyloid deposits. Here we report that there are numerous intraneuronal NFT and extraneuronal NFT immunoreactive for Aβx-40 in which there is no co-localization with tau staining suggesting the existence of two different neurodegenerating populations associated with the intracellular accumulation of either tau protein or Aβx-40 in AD.
View Article and Find Full Text PDF